Service providers

Delphi Genetics

Solution provided
Technological/Validation solutions
Supplier indentity
General description
Delphi Genetics was founded in November 2001. It is a spin-off company of the University of Brussels located in Gosselies Belgium. Delphi Genetics is active in the field of molecular biology and more precisely in bioproductions (proteins DNA). The company develops technolgogies to produce recombinant proteins and DNA with higher yields and without antibiotic resistance genes. Delphi Genetics is also providing several services as gene synthesis protein production antibody development...
Type of supplier
Biotechnology Company - Therapeutics, Bioprocess Solutions Provider
Sector of activity:
Biomanufacturing, Drug Discovery / Research & Development, Gene / Cell Therapy, In vitro Diagnostics, Molecular biology
Activity description
Services provided
Terms of availability for SMEs
Delphi Genetics has developed the Staby(R) technology to replace antibiotic-resistance genes by a selection system that uses two natural bacterial genes (see below).|Delphi Genetics is also providing several services to industries and academic laboratories based on its technologies or only on the know-how of its researchers:|-Gene synthesis|-Sequence optimization for protein production|-DNA cloning and mutagenesis|-plasmid stabilization without antibiotics (Staby(R) technology)|-plasmid DNA production (non-GMP)|-Customized protein production (non-GMP)|-In-house genome sequencing and analysis|-Q-PCR analysis|-Customized strain adaptations|-Polyclonal and Monoclonal antibody development based on unique technology for difficult-to-produce antigens, Delphi Genetics is ISO9001:2008 certified, demonstrating the high standards of quality in providing customer services and technologies.|The Staby(R) technology, The Staby technology is consistent with the recommendations of the FDA and EMA with regard to elimination of Antibiotic Resistance Genes in protein production processes for both human and veterinary uses. The Staby(R) technology is already used successfully for production of recombinant proteins in E. coli to achieve higher yields and using antibiotics-free media. The technology is licensed to Sanofi-Pasteur and GSK for production of human recombinant proteins used as vaccines. Delphi Genetics is now developing the application of the technology to the field of DNA vaccines in order to avoid completely the use of antibiotics resistance genes from DNA cloning to DNA production. Other research projects are under way to adapt the technology to mammalian cells and yeast.|For more information, please, see our website (www.delphigenetics.com ) or send us an email to delphigenetics(at)delphigenetics.com
Quality labels and accreditations
Delphi Genetics is ISO9001:2008 certified, demonstrating the high standards of quality in providing customer services and technologies.
Contact information
Name
Cedric Szpirer
Function
CEO / CSO
Phone number
+32 (0) 71 25 10 00
Website
Address

Agenda

Mo Tu We Th Fr Sa Su
1
 
2
 
3
 
4
 
5
 
6
 
7
 
8
 
9
 
10
 
11
 
12
 
13
 
14
 
15
 
16
 
17
 
18
 
19
 
20
 
21
 
22
 
23
 
24
 
25
 
26
 
27
 
28
 
29
 
30
 
31